Matches in Nanopublications for { ?s <http://www.w3.org/2000/01/rdf-schema#label> ?o ?g. }
- association label "Although antidepressants are not the first-line prophylactic strategy for patients with migraine, several clinical trials have proven their effectiveness in the treatment of migraine and related headache disorders (Koch and Jurgens, 2009). Especially TCAs: amitriptyline (Couch and Hassanein, 1979; Jackson et al., 2010; Kalita et al., 2013) and nortriptyline (Holroyd et al., 2001; Jackson et al., 2010) have the best evidence for use in migraine prevention. When amitriptyline is not tolerated by patients, treatment is continued with nortriptyline (Burch, 2019)." assertion.
- context label "Adults" assertion.
- context label "Adults" assertion.
- association label "Although antidepressants are not the first-line prophylactic strategy for patients with migraine, several clinical trials have proven their effectiveness in the treatment of migraine and related headache disorders (Koch and Jurgens, 2009). Especially TCAs: amitriptyline (Couch and Hassanein, 1979; Jackson et al., 2010; Kalita et al., 2013) and nortriptyline (Holroyd et al., 2001; Jackson et al., 2010) have the best evidence for use in migraine prevention. When amitriptyline is not tolerated by patients, treatment is continued with nortriptyline (Burch, 2019)." assertion.
- association label "Among TCAs, doxepin (sinequan) appears to be best suited for managing insomnia in healthy adults. Doxepin works as a selective antagonist to H(1) receptors, which promote the initiation and maintenance of sleep (Owen, 2009) (Table 2). Ultra-low doses of this drug (< 6 mg per day) significantly improve and sustain both maintenance and duration of sleep (Rojas-Fernandez and Chen, 2014; Weber et al., 2010). Another frequently prescribed TCA is amitriptyline, which as a long-term option is found to be effective for patients with ongoing sleep problems (Everitt et al., 2014; Pagel and Parnes, 2001)." assertion.
- context label "Adults" assertion.
- MONDO_0100081 label "sleep disorder" assertion.
- MONDO_0100081 label "sleep disorder" assertion.
- MONDO_0100081 label "sleep disorder" assertion.
- MONDO_0100081 label "sleep disorder" assertion.
- MONDO_0100081 label "sleep disorder" assertion.
- MONDO_0100081 label "sleep disorder" assertion.
- MONDO_0100081 label "sleep disorder" assertion.
- MONDO_0100081 label "sleep disorder" assertion.
- MONDO_0100081 label "sleep disorder" assertion.
- MONDO_0100081 label "sleep disorder" assertion.
- MONDO_0100081 label "sleep disorder" assertion.
- MONDO_0100081 label "sleep disorder" assertion.
- MONDO_0100081 label "sleep disorder" assertion.
- MONDO_0100081 label "sleep disorder" assertion.
- MONDO_0100081 label "sleep disorder" assertion.
- MONDO_0100081 label "sleep disorder" assertion.
- MONDO_0100081 label "Sleep disorder" assertion.
- association label "Among TCAs, doxepin (sinequan) appears to be best suited for managing insomnia in healthy adults. Doxepin works as a selective antagonist to H(1) receptors, which promote the initiation and maintenance of sleep (Owen, 2009) (Table 2 contains information on trazodone and mirtazapine). Ultra-low doses of this drug (< 6 mg per day) significantly improve and sustain both maintenance and duration of sleep (Rojas-Fernandez and Chen, 2014; Weber et al., 2010). Another frequently prescribed TCA is amitriptyline, which as a long-term option is found to be effective for patients with ongoing sleep problems (Everitt et al., 2014; Pagel and Parnes, 2001)." assertion.
- context label "Adults" assertion.
- context label "Adults" assertion.
- association label "(Osland et al., 2018; Otasowie et al., 2014) information extracted from Table 2." assertion.
- context label "Adults" assertion.
- association label "Attitudes on off-label use of Asenapine in the treatment of BPD: Highly inappropriate = 97 (48.0%); Innapropriate = 24 (11.9%); Doubt = 60 (29.7%); Appropriate = 21 (10.4%); Highly appropriate = 0 (0%) " assertion.
- association label "The SGA olanzapine is considered the most appropriate, followed by quetiapine and aripiprazole. Although off-label prescription of SGAs represents a common clinical practice in accordance with a worldwide trend, the use of long-acting injection formulations was considered inappropriate by 69% of psychiatrists in our sample. Attitudes on off-label use of Olanzapine in the treatment of BPD: Highly inappropriate = 26 (12.9%); Innapropriate = 26 (12.9%); Doubt = 86 (42.5%); Appropriate = 64 (31.7%); Highly appropriate = 0 (0%) " assertion.
- context label "Adults" assertion.
- context label "Adults" assertion.
- association label "The SGA olanzapine is considered the most appropriate, followed by quetiapine and aripiprazole. Although off-label prescription of SGAs represents a common clinical practice in accordance with a worldwide trend, the use of long-acting injection formulations was considered inappropriate by 69% of psychiatrists in our sample.Attitudes on off-label use of Quetiapine in the treatment of BPD: Highly inappropriate = 50 (24.8%); Innapropriate = 20 (9.9%); Doubt = 75 (37.1%); Appropriate = 52 (25.7%); Highly appropriate = 5 (2.5%) " assertion.
- context label "Adults" assertion.
- association label "Attitudes on off-label use of Ziprasidone in the treatment of BPD: Highly inappropriate = 167 (82.7%); Innapropriate = 12 (5.9%); Doubt = 18 (8.9%); Appropriate = 5 (2.5%); Highly appropriate = 0 (0%) " assertion.
- context label "Adults" assertion.
- association label "The on‐label indication for Brintellix is depression; we identified the following off‐label indications: schizophrenia, episodic mood disorders, anxiety disorders, personality disorders, bipolar depression, post‐traumatic stress disorder, and chronic pain." assertion.
- MONDO_0005371 label "Mood disorder" assertion.
- MONDO_0005371 label "mood disorder" assertion.
- context label "Adults" assertion.
- association label "The on‐label indication for Brintellix is depression; we identified the following off‐label indications: schizophrenia, episodic mood disorders, anxiety disorders, personality disorders, bipolar depression, post‐traumatic stress disorder, and chronic pain." assertion.
- MONDO_0002028 label "Personality disorder (disease)" assertion.
- context label "Adults" assertion.
- association label "The on‐label indication for Brintellix is depression; we identified the following off‐label indications: schizophrenia, episodic mood disorders, anxiety disorders, personality disorders, bipolar depression, post‐traumatic stress disorder, and chronic pain." assertion.
- association label "Although not approved for the treatment of ADHD, clonidine and atypical antipsychotics (AAPs) are commonly used off-label in ADHD, especially when stimulants fail." assertion.
- context label "Children and adolescents" assertion.
- context label "Adults" assertion.
- association label "Milnacipran is not currently FDA approved for the treatment of major depression. However, this is a frequent off-label application both within the USA and internationally." assertion.
- context label "Adults" assertion.
- association label "For maintenance treatment of BD, off-label asenapine was considered appropriate by 45% of the psychiatrists, followed by long-acting aripiprazole and olanzapine pamoate, which were considered appropriate by 37.1% and 23.8%, respectively. In summary, ~50% of Italian psychiatrists frequently (very often or often) prescribe SGAs for off-label indications. " assertion.
- association label "With regard to the use of specific SGAs in BD, off-label aripiprazole was considered appropriate for depressive episodes by 46% of the psychiatrists, followed by olanzapine which was considered appropriate by 33.7%." assertion.
- context label "Adults" assertion.
- association label "When we asked about the long-term treatment of BD, after having excluded from the analyses the 3 SGAs with a European indication for maintenance BD treatment (aripiprazole, olanzapine, and quetiapine), asenapine was considered either “highly appropriate” or “appropriate” by 44.6% of the respondents, while other off-label SGAs (clozapine, paliperidone, risperidone, ziprasidone) were mostly considered inappro- priate for maintenance bipolar treatment" assertion.
- context label "Adults" assertion.
- context label "Children and adolescents" assertion.
- association label "Fluoxetine and escitalopram are the only agents with Food and Drug Administration approval for pediatric depression, but off-label bupropion prescriptions are common. " assertion.
- context label "Adults" assertion.
- association label "The off label antipsychotic treatments we considered were sulpiride, olanzapine, pimozide, quetiapine, risperidone, haloperidol, tiapride, chlorpromazine, and aripiprazole. We estimated the effect of antipsychotics as a group, and also estimated effects of certain individual antipsychotic chorea drugs (i.e. olanzapine, risperidone, and tiapride) commonly taken in our cohort." assertion.
- context label "Adults" assertion.
- association label "The off label antipsychotic treatments we considered were sulpiride, olanzapine, pimozide, quetiapine, risperidone, haloperidol, tiapride, chlorpromazine, and aripiprazole. We estimated the effect of antipsychotics as a group, and also estimated effects of certain individual antipsychotic chorea drugs (i.e. olanzapine, risperidone, and tiapride) commonly taken in our cohort." assertion.
- association label "The off label antipsychotic treatments we considered were sulpiride, olanzapine, pimozide, quetiapine, risperidone, haloperidol, tiapride, chlorpromazine, and aripiprazole. We estimated the effect of antipsychotics as a group, and also estimated effects of certain individual antipsychotic chorea drugs (i.e. olanzapine, risperidone, and tiapride) commonly taken in our cohort." assertion.
- context label "Adults" assertion.
- association label "The off label antipsychotic treatments we considered were sulpiride, olanzapine, pimozide, quetiapine, risperidone, haloperidol, tiapride, chlorpromazine, and aripiprazole. We estimated the effect of antipsychotics as a group, and also estimated effects of certain individual antipsychotic chorea drugs (i.e. olanzapine, risperidone, and tiapride) commonly taken in our cohort." assertion.
- context label "Adults" assertion.
- association label "The off label antipsychotic treatments we considered were sulpiride, olanzapine, pimozide, quetiapine, risperidone, haloperidol, tiapride, chlorpromazine, and aripiprazole. We estimated the effect of antipsychotics as a group, and also estimated effects of certain individual antipsychotic chorea drugs (i.e. olanzapine, risperidone, and tiapride) commonly taken in our cohort." assertion.
- context label "Adults" assertion.
- association label ""Fenoglide is contraindicated in patients with severe renal dysfunction, including those receiving dialysis [see Clinical Pharmacology (12.3) Fenoglide is contraindicated in patients with active liver disease, including those with primary biliary cirrhosis and unexplained persistent liver function abnormalities [see Warnings and Precautions (5.1) Fenoglide is contraindicated in patients with gallbladder disease [see Warnings and Precautions (5.2) Fenoglide is contraindicated in nursing mothers [see Use in Specific Populations (8.3) Fenoglide is contraindicated in patients who have a known hypersensitivity to fenofibrate, such as severe skin rashes, including Stevens-Johnson syndrome and toxic epidermal necrolysis. [see Warnings and Precautions (5.9) Severe renal dysfunction, including patients receiving dialysis ( 4 12.3 Active liver disease ( 4 5.1 Gallbladder disease ( 4 5.2 Nursing mothers ( 4 8.3"" assertion.
- association label ""CONTRAINDICATIONS Epithelial herpes simplex keratitis (dendritic keratitis). Acute infectious stages of vaccinia, varicella and many other viral diseases of the cornea and conjunctiva. Mycobacterial infection of the eye. Fungal diseases of ocular or auricular structures. Hypersensitivity to any component of this product, including sulfites (see WARNINGS Perforation of a drum membrane."" assertion.
- association label ""Active liver disease, which may include unexplained persistent elevations in hepatic transaminase levels (4.1) Women who are pregnant or may become pregnant (4.3) Nursing mothers (4.4). Hypersensitivity to any component of this medication (4.2) Active liver disease which may include unexplained persistent elevations of hepatic transaminase levels Hypersensitivity to any component of this medication Women who are pregnant or may become pregnant. Atorvastatin calcium may cause fetal harm when administered to a pregnant woman. Serum cholesterol and triglycerides increase during normal pregnancy, and cholesterol or cholesterol derivatives are essential for fetal development. Atherosclerosis is a chronic process and discontinuation of lipid-lowering drugs during pregnancy should have little impact on the outcome of long-term therapy of primary hypercholesterolemia. There are no adequate and well-controlled studies of atorvastatin calcium use during pregnancy; however in rare reports, congenital anomalies were observed following intrauterine exposure to statins. In rat and rabbit animal reproduction studies, atorvastatin revealed no evidence of teratogenicity. ATORVASTATIN CALCIUM SHOULD BE ADMINISTERED TO WOMEN OF CHILDBEARING AGE ONLY WHEN SUCH PATIENTS ARE HIGHLY UNLIKELY TO CONCEIVE AND HAVE BEEN INFORMED OF THE POTENTIAL HAZARDS. If the patient becomes pregnant while taking this drug, atorvastatin calcium should be discontinued immediately and the patient apprised of the potential hazard to the fetus [see Use in Specific Populations (8.1 ) It is not known whether atorvastatin is excreted into human milk; however a small amount of another drug in this class does pass into breast milk. Because statins have the potential for serious adverse reactions in nursing infants, women who require atorvastatin calcium treatment should not breastfeed their infants [see Use in Specific Populations (8.3)"" assertion.
- association label ""CONTRAINDICATIONS Obstructive uropathy Obstructive disease of the gastrointestinal tract Severe ulcerative colitis (See ) PRECAUTIONS Reflux esophagitis Unstable cardiovascular status in acute hemorrhage Glaucoma Myasthenia gravis Evidence of prior hypersensitivity to dicyclomine hydrochloride or other ingredients of this formulation Infants less than 6 months of age (See and : .) WARNINGS PRECAUTIONS Information for Patients Nursing Mothers (See and : .) WARNINGS PRECAUTIONS Information for Patients"" assertion.
- association label ""PRINIVIL is contraindicated in patients with: a history of angioedema or hypersensitivity related to previous treatment with an angiotensin converting enzyme inhibitor hereditary or idiopathic angioedema. Do not coadminister aliskiren with PRINIVIL in patients with diabetes [see Drug Interactions (7.4) PRINIVIL is contraindicated in combination with a neprilysin inhibitor (e.g., sacubitril). Do not administer PRINIVIL within 36 hours of switching to or from sacubitril/valsartan, a product containing a neprilysin inhibitor [see Warnings and Precautions (5.2) Drug Interactions (7.8) Angioedema or a history of hereditary or idiopathic angioedema ( 4 Hypersensitivity ( 4 Coadministration of aliskiren with PRINIVIL in patients with diabetes ( 4 7.4 PRINIVIL is contraindicated in combination with a neprilysin inhibitor (e.g., sacubitril). Do not administer PRINIVIL within 36 hours of switching to or from sacubitril/valsartan, a product containing a neprilysin inhibitor ( 4"" assertion.
- association label ""Quinapril tablets are contraindicated in patients who are hypersensitive to this product and in patients with a history of angioedema related to previous treatment with an ACE inhibitor. Quinapril tablets are contraindicated in combination with a neprilysin inhibitor (e.g., sacubitril). Do not administer quinapril tablets are within 36 hours of switching to or from sacubitril/valsartan, a neprilysin inhibitor (see WARNINGS PRECAUTIONS Do not co-administer quinapril tablets with aliskiren in patients with diabetes"" assertion.
- association label ""SORINE (sotalol hydrochloride) tablets are contraindicated in patients with: Sinus bradycardia, sick sinus syndrome, second and third degree AV block, unless a functioning pacemaker is present Congenital or acquired long QT syndromes Cardiogenic shock or decompensated heart failure Serum potassium <4 mEq/L Bronchial asthma or related bronchospastic conditions Hypersensitivity to sotalol For the treatment of AFIB/AFL, SORINE (sotalol hydrochloride) tablets are also contraindicated in patients with: Baseline QT interval >450 ms Creatinine clearance <40 mL/min For the treatment of AFIB/AFL or ventricular arrhythmias Sinus bradycardia, 2 nd rd 4 Congenital or acquired long QT syndrome ( 4 Serum potassium <4 mEq/L( 4 Cardiogenic shock, decompensated heart failure ( 4 Bronchial asthma or related bronchospastic conditions ( 4 Hypersensitivity to sotalol ( 4 For the treatment of AFIB/AFL also contraindicated for: QT interval >450 ms ( 4 Creatinine clearance <40 mL/min ( 4"" assertion.
- association label ""Enalapril maleate tablets, USP are contraindicated in patients who are hypersensitive to this product and in patients with a history of angioedema related to previous treatment with an angiotensin-converting enzyme inhibitor and in patients with hereditary or idiopathic angioedema. Do not coadminister aliskiren with enalapril maleate in patients with diabetes (see PRECAUTIONS, Drug Interactions Enalapril maleate tablets, USP are contraindicated in combination with a neprilysin inhibitor (e.g., sacubitril). Do not administer enalapril maleate tablets USP within 36 hours of switching to or from sacubitril/valsartan, a neprilysin inhibitor (see WARNINGS , Head and Neck Angioedema"" assertion.
- association label ""Prednisolone acetate ophthalmic suspension 1% is contraindicated in acute untreated purulent ocular infections, in most viral diseases of the cornea and conjunctiva including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, and varicella, and also in mycobacterial infection of the eye and fungal diseases of ocular structures. Prednisolone acetate ophthalmic suspension 1% is also contraindicated in individuals with known or suspected hypersensitivity to any of the ingredients of this preparation and to other corticosteroids."" assertion.
- association label ""Verapamil is contraindicated in: Severe left ventricular dysfunction [ see Warnings and Precautions (5.1) Hypotension (less than 90 mm Hg systolic pressure) or cardiogenic shock. Sick sinus syndrome (except in patients with a functioning artificial ventricular pacemaker). Second- or third-degree AV block (except in patients with a functioning artificial ventricular pacemaker). Patients with atrial flutter or atrial fibrillation and an accessory bypass tract (e.g., Wolff-Parkinson-White, Lown-Ganong-Levine syndromes) [ see Warnings and Precautions (5.4) Severe left ventricular dysfunction ( 4 Hypotension (<90 mmHg systolic pressure) or cardiogenic shock ( 4 Sick sinus syndrome (except in patients with pacemaker) ( 4 2nd- or 3rd-degree AV block (except in patients with pacemaker) ( 4 Atrial flutter or atrial fibrillation and an accessory bypass tract ( 4"" assertion.
- association label "Severe renal impairment with oliguria or azotemia, untreated Addison's disease, or severe myocardial damage. In certain situations, when patients are on a sodium-restricted diet, the use of potassium citrate may be preferable; or, when patients are on a potassium-restricted diet, the use of sodium citrate may be preferable." assertion.
- association label ""Uncontrolled hypertension and sensitivity to any ergot alkaloids. In patients being treated for hyperprolactinemia, bromocriptine mesylate tablets and capsules should be withdrawn when pregnancy is diagnosed (see PRECAUTIONS: Hyperprolactinemic States PRECAUTIONS: Hyperprolactinemic States The drug should not be used during the postpartum period in women with a history of coronary artery disease and other severe cardiovascular conditions unless withdrawal is considered medically contraindicated. If the drug is used in the postpartum period the patient should be observed with caution."" assertion.
- association label ""Risedronate Sodium is contraindicated in patients with the following conditions: Abnormalities of the esophagus which delay esophageal emptying such as stricture or achalasia [ see Warnings and Precautions ( 5.1 ) Inability to stand or sit upright for at least 30 minutes [ see Dosage and Administration ( 2 ), Warnings and Precautions ( 5.1 ) Hypocalcemia [ see Warnings and Precautions ( 5.2 ) Known hypersensitivity to Risedronate Sodium or any of its excipients. Angioedema, generalized rash, bullous skin reactions, Stevens-Johnson syndrome and toxic epidermal necrolysis have been reported [ see Adverse Reactions ( 6.2 ) Abnormalities of the esophagus which delay esophageal emptying such as stricture or achalasia ( 4 5.1 Inability to stand or sit upright for at least 30 minutes ( 4 5.1 Hypocalcemia ( 4 5.2 Known hypersensitivity to any component of this product ( 4 6.2"" assertion.
- association label ""Anuria Known hypersensitivity to chlorthalidone tablets or other sulfonamide-derived drugs."" assertion.
- association label ""Coadministration of a number of CYP3A4 substrates such as dofetilide, quinidine cisapride and pimozide is contraindicated with ketoconazole tablets. Coadministration with ketoconazole can cause elevated plasma concentrations of these drugs and may increase or prolong both therapeutic and adverse effects to such an extent that a potentially serious adverse reaction may occur. For example, increased plasma concentrations of some of these drugs can lead to QT prolongation and sometimes resulting in life-threatening ventricular tachyarrhythmias including occurrences of torsades de pointes, a potentially fatal arrhythmia. (See PRECAUTIONS: Drug Interactions Additionally, the following other drugs are contraindicated with ketoconazole tablets: methadone, disopyramide, dronedarone, ergot alkaloids such as dihydroergotamine, ergometrine, ergotamine, methylergometrine, irinotecan, lurasidone, oral midazolam, alprazolam, triazolam, felodipine, nisoldipine, ranolazine, tolvaptan, eplerenone, lovastatin, simvastatin and colchicine. (See PRECAUTIONS: Drug Interactions Coadministration of ketoconazole tablets with oral midazolam, oral triazolam or alprazolam has resulted in elevated plasma concentrations of these drugs. This may potentiate and prolong hypnotic and sedative effects, especially with repeated dosing or chronic administration of these agents. Concomitant administration of ketoconazole tablets with oral triazolam, oral midazolam or alprazolam is contraindicated. (See PRECAUTIONS: Drug Interactions Coadministration of CYP3A4 metabolized HMG-CoA reductase inhibitors such as simvastatin, and lovastatin is contraindicated with ketoconazole tablets. (See PRECAUTIONS: Drug Interactions Concomitant administration of ergot alkaloids such as dihydroergotamine and ergotamine with ketoconazole tablets is contraindicated. (See PRECAUTIONS: Drug Interactions The use of ketoconazole tablets is contraindicated in patients with acute or chronic liver disease. Ketoconazole tablets USP, 200 mg is contraindicated in patients who have shown hypersensitivity to the drug."" assertion.
- association label "Glaucoma; obstructive uropathy (for example, bladder neck obstruction due to prostatic hypertrophy); obstructive disease of the gastrointestinal tract (as in achalasia, pyloroduodenal stenosis); paralytic ileus, intestinal atony of elderly or debilitated patients; unstable cardiovascular status in acute hemorrhage; severe ulcerative colitis; toxic megacolon complicating ulcerative colitis; myasthenia gravis and myocardial ischemia." assertion.
- association label ""* (4.1) Surgical placement of RETISERT is contraindicated in active viral diseases of the cornea and conjunctiva including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, and varicella, and also in active bacterial, mycobacterial or fungal infections of the eye."" assertion.
- association label ""Rizatriptan benzoate tablets are contraindicated in patients with: * Ischemic coronary artery disease (angina pectoris, history of myocardial infarction, or documented silent ischemia), or other significant underlying cardiovascular disease [see Warnings and Precautions ( 5.1 * Coronary artery vasospasm including Prinzmetal's angina [see Warnings and Precautions ( 5.1 * History of stroke or transient ischemic attack (TIA) [see Warnings and Precautions ( 5.4 * Peripheral vascular disease (PVD) [see Warnings and Precautions ( 5.5 * Ischemic bowel disease [see Warnings and Precautions ( 5.5 * Uncontrolled hypertension [see Warnings and Precautions ( 5.8 * Recent use (i.e., within 24 hours) of another 5-HT 1 [see Drug Interactions ( 7.2 7.3 * Hemiplegic or basilar migraine. * Concurrent administration or recent discontinuation (i.e., within 2 weeks) of a MAO-A inhibitor [see Drug Interactions ( 7.5 12.3 * Hypersensitivity to rizatriptan benzoate tablets or rizatriptan benzoate orally disintegrating tablets (angioedema and anaphylaxis seen) [see Adverse Reactions ( 6.2 * History of ischemic heart disease or coronary artery vasospasm ( 4 * History of stroke or transient ischemic attack ( 4 * Peripheral vascular disease ( 4 * Ischemic bowel disease ( 4 * Uncontrolled hypertension ( 4 * Recent (within 24 hours) use of another 5-HT 1 4 * Hemiplegic or basilar migraine ( 4 * MAO-A inhibitor used in the past 2 weeks ( 4 * Hypersensitivity to rizatriptan benzoate( 4"" assertion.
- association label ""Pulmonary hypertension, advanced arteriosclerosis, hyperthyroidism, known hypersensitivity or idiosyncrasy to the sympathomimetic amines, glaucoma, severe hypertension. (See .) PRECAUTIONS Agitated states. Patients with a history of drug abuse. Use in combination with other anorectic agents is contraindicated. During or within 14 days following the administration of monoamine oxidase inhibitors, hypertensive crises may result."" assertion.
- association label ""Naratriptan tablets are contraindicated in patients with: Ischemic coronary artery disease (CAD) (angina pectoris, history of myocardial infarction, or documented silent ischemia) or coronary artery vasospasm, including Prinzmetal's angina [see Warnings and Precautions (5.1) ] Wolff-Parkinson-White syndrome or arrhythmias associated with other cardiac accessory conduction pathway disorders [see Warnings and Precautions (5.2) ] History of stroke or transient ischemic attack (TIA) or history of hemiplegic or basilar migraine because such patients are at a higher risk of stroke [see Warnings and Precautions (5.4) ] Peripheral vascular disease [see Warnings and Precautions (5.5) ] Ischemic bowel disease [see Warnings and Precautions (5.5) ] Uncontrolled hypertension [see Warnings and Precautions (5.8) ] Recent use (i.e., within 24 hours) of another 5-HT 1 agonist, ergotamine-containing medication, ergot-type medication (such as dihydroergotamine or methysergide) [see Drug Interactions (7.1, 7.2)] Hypersensitivity to naratriptan (angioedema and anaphylaxis seen) [see Warnings and Precautions (5.9)] Severe renal or hepatic impairment [see Use in Specific Populations (8.6, 8.7), Clinical Pharmacology (12.3)] History of coronary artery disease or coronary artery vasospasm (4) Wolff-Parkinson-White syndrome or other cardiac accessory conduction pathway disorders (4) History of stroke, transient ischemic attack, or hemiplegic or basilar migraine (4) Peripheral vascular disease (4) Ischemic bowel disease (4) Uncontrolled hypertension (4) Recent (within 24 hours) use of another 5-HT 1 agonist (e.g., another triptan) or an ergotamine-containing medication (4) Hypersensitivity to naratriptan (angioedema and anaphylaxis seen) (4) Severe renal or hepatic impairment (4)"" assertion.
- association label ""History of Clozapine-induced Agranulocytosis or Severe Granulocytopenia CLOZARIL is contraindicated in patients with a history of clozapine-induced agranulocytosis or severe granulocytopenia . [see Warnings and Precautions (5.1)] Hypersensitivity CLOZARIL is contraindicated in patients with a history of hypersensitivity to clozapine (e.g., photosensitivity, vasculitis, erythema multiforme, or Stevens-Johnson syndrome) or any other component of CLOZARIL . [see Adverse Reactions (6.2)] History of clozapine-induced agranulocytosis or severe Granulocytopenia. ( ) 4 Known hypersensitivity to clozapine or any other component of CLOZARIL. ( ) 4"" assertion.
- association label ""Acute intermittent porphyria (4) Hypersensitivity reactions to a carbamate such as meprobamate (4)"" assertion.
- association label ""Frovatriptan succinate tablets are contraindicated in patients with: Ischemic coronary artery disease (CAD) (e.g., angina pectoris, history of myocardial infarction, or documented silent ischemia), or coronary artery vasospasm, including Prinzmetal's angina [see Warnings and Precautions ( 5.1 Wolff-Parkinson-White Syndrome or arrhythmias associated with other cardiac accessory conduction pathway disorders [see Warnings and Precautions ( 5.2 History of stroke, transient ischemic attack (TIA), or history of hemiplegic or basilar migraine because these patients are at a higher risk of stroke [s ee Warnings and Precautions ( 5.4 Peripheral vascular disease [s ee Warnings and Precautions ( 5.5 Ischemic bowel disease [s ee Warnings and Precautions ( 5.5 Uncontrolled hypertension [see Warnings and Precautions ( 5.8 Recent use (i.e., within 24 hours) of another 5-HT 1 [see Drug Interactions ( 7.1 7.2 Hypersensitivity to frovatriptan succinate (angioedema and anaphylaxis seen) [s ee Warnings and Precautions ( 5.9 History of coronary artery disease or coronary artery vasospasm ( 4 Wolff-Parkinson-White syndrome or other cardiac accessory conduction pathway disorders ( 4 History of stroke, transient ischemic attack, or hemiplegic or basilar migraine ( 4 Peripheral vascular disease ( 4 Ischemic bowel disease ( 4 Uncontrolled hypertension ( 4 Recent (within 24 hours) use of treatment with another 5-HT 1 4 Hypersensitivity to frovatriptan succinate tablets (angioedema and anaphylaxis seen) ( 4"" assertion.
- association label ""Administration of Mifepristone tablets, 200mg and misoprostol for the termination of pregnancy (the ""treatment procedure"") is contraindicated in patients with any of the following conditions: - [ see Warnings and Precautions ( 5.4 - - - [ see Adverse Reactions ( 6.2 - - Use of Mifepristone tablets, 200mg and misoprostol for termination of intrauterine pregnancy is contraindicated in patients with an intrauterine device (""IUD"") in place (the IUD might interfere with pregnancy termination). If the IUD is removed, Mifepristone tablets, 200mg may be used. Confirmed/suspected ectopic pregnancy or undiagnosed adnexal mass ( 4 Chronic adrenal failure ( 4 Concurrent long-term corticosteroid therapy ( 4 History of allergy to mifepristone, misoprostol, or other prostaglandins ( 4 Hemorrhagic disorders or concurrent anticoagulant therapy ( 4 Inherited porphyria ( 4 Intrauterine device (IUD) in place ( 4"" assertion.
- association label ""DESCRIPTION WARNINGS: Anaphylactic / Anaphylactoid Reactions PRECAUTIONS: General: Preexisting Asthma WARNINGS"" assertion.
- association label ""Anuria. Severe or progressive kidney disease or dysfunction, with the possible exception of nephrosis. Severe hepatic disease. Hypersensitivity to the drug or any of its components. Triamterene capsules should not be used in patients with pre-existing elevated serum potassium, as is sometimes seen in patients with impaired renal function or azotemia, or in patients who develop hyperkalemia while on the drug. Patients should not be placed on dietary potassium supplements, potassium salts or potassium-containing salt substitutes in conjunction with triamterene capsules. Triamterene capsules should not be given to patients receiving other potassium-sparing agents, such as spironolactone, amiloride hydrochloride, or other formulations containing triamterene. Two deaths have been reported in patients receiving concomitant spironolactone and triamterene capsules or Dyazide (r) Abnormal elevation of serum potassium levels (greater than or equal to 5.5 mEq/liter) can occur with all potassium-sparing agents, including triamterene capsules. Hyperkalemia is more likely to occur in patients with renal impairment and diabetes (even without evidence of renal impairment), and in the elderly or severely ill. Since uncorrected hyperkalemia may be fatal, serum potassium levels must be monitored at frequent intervals especially in patients receiving triamterene capsules, when dosages are changed or with any illness that may influence renal function."" assertion.
- association label ""* Use of phosphodiesterase type 5 (PDE-5) inhibitors, such as avanafil, sildenafil, tadalafil, or vardenafil, or soluble guanylate cyclase (sGC) stimulators. (4.1, 7.1) * Severe anemia (4.2) * Increased intracranial pressure (4.3) * Hypersensitivity to nitroglycerin sublingual tablets or to other nitrates or nitrites or any excipient (4.4) * Circulatory failure and shock (4.5) Do not use nitroglycerin sublingual tablets in patients who are taking PDE-5 Inhibitors, such as avanafil, sildenafil, tadalafil, vardenafil hydrochloride. Concomitant use can cause severe hypotension, syncope, or myocardial ischemia [see Drug Interactions ( 7.1 Do not use nitroglycerin sublingual tablets in patients who are taking the soluble guanylate cyclase stimulators, such as riociguat. Concomitant use can cause hypotension. Nitroglycerin sublingual tablets are contraindicated in patients with severe anemia (large doses of nitroglycerin may cause oxidation of hemoglobin to methemoglobin and could exacerbate anemia). Nitroglycerin sublingual tablets may precipitate or aggravate increased intracranial pressure and thus should not be used in patients with possible increased intracranial pressure (e.g., cerebral hemorrhage or traumatic brain injury). Nitroglycerin sublingual tablets are contraindicated in patients who are allergic to nitroglycerin, other nitrates or nitrites or any excipient. Nitroglycerin sublingual tablets are contraindicated in patients with acute circulatory failure or shock."" assertion.
- association label ""VYLEESI is contraindicated in patients who have uncontrolled hypertension or known cardiovascular disease [see Warnings and Precautions ( 5.1 Uncontrolled hypertension or known cardiovascular disease. ( 4"" assertion.
- association label "Perindopril erbumine tablets are contraindicated in patients known to be hypersensitive to this product or to any other ACE inhibitor. Perindopril erbumine tablets are also contraindicated in patients with a history of angioedema related to previous treatment with an ACE inhibitor." assertion.
- association label ""The use of Desflurane, USP, Liquid for Inhalation is contraindicated in the following conditions: Known or suspected genetic susceptibility to malignant hyperthermia. Patients in whom general anesthesia is contraindicated. Induction of anesthesia in pediatric patients. Patients with known sensitivity to Desflurane, USP, Liquid for Inhalation or to other halogenated agents [See Warnings and Precautions (5.6) ] Patients with a history of moderate to severe hepatic dysfunction following anesthesia with Desflurane, USP, Liquid for Inhalation or other halogenated agents and not otherwise explained [See Warnings and Precautions (5.6) ] Patients with known or suspected genetic susceptibility to malignant hyperthermia ( 4 Patients in whom general anesthesia is contraindicated ( 4 Induction of anesthesia in pediatric patients ( 4 Patients with known sensitivity to halogenated agents ( 4 Patients with a history of moderate to severe hepatic dysfunction following anesthesia with halogenated agents and not otherwise explained. ( 4"" assertion.
- association label "Ethambutol hydrochloride tablets are contraindicated in patients who are known to be hypersensitive to this drug. It is also contraindicated in patients with known optic neuritis unless clinical judgment determines that it may be used. Ethambutol hydrochloride tablets are contraindicated in patients who are unable to appreciate and report visual side ettects or changes in vision (e.g., young children, unconscious patients)." assertion.
- association label "RIDAURA (auranofin) is contraindicated in patients with a history of any of the following gold-induced disorders: anaphylactic reactions, necrotizing enterocolitis, pulmonary fibrosis, exfoliative dermatitis, bone marrow aplasia or other severe hematologic disorders." assertion.
- association label ""In patients who are hypersensitive to the drug or its ingredients. Phenazopyridine is contraindicated in patients with renal insufficiency, severe liver disease, severe hepatitis or pyelonephritis of pregnancy. It should be used cautiously in the presence of GI disturbances."" assertion.
- association label ""Paricalcitol injection is contraindicated in patients with: Hypercalcemia [see Warnings and Precautions ( 5.1 Vitamin D toxicity [see Warnings and Precautions ( 5.1 Known hypersensitivity to paricalcitol or any of the inactive ingredients in paricalcitol injection. Hypersensitivity adverse reactions have been reported [e.g., angioedema (including laryngeal edema) and urticaria] [see Adverse Reactions ( 6.2 Hypercalcemia ( 4 Vitamin D toxicity ( 4 Known hypersensitivity to paricalcitol or any inactive ingredient ( 4"" assertion.